In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods

被引:28
作者
Lewis, RE
Klepser, ME
Pfaller, MA
机构
[1] Univ Iowa, Coll Pharm, Iowa City, IA 52242 USA
[2] Univ Iowa, Coll Med, Iowa City, IA USA
关键词
D O I
10.1016/S0732-8893(99)00125-X
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Two Candida albicans isolates, three non-albicans Candida isolates (Candida glabrata, Candida krusei, and Candida tropicalis), and one Cryptococcus neoformans isolate were evaluated by time-kill methods to characterize the relationship of flucytosine concentrations to antifungal activity and the duration of the post-antifungal effect (PAE). Against Candida and Cryptococcus isolates, flucytosine at concentrations > 1 x MIC exhibited fungistatic (less than or equal to 99% reduction in CFU) activity over a 24-h time-period. The rate and extent of fungistatic activity of flucytosine against all isolates was generally not increased when 5-FC concentrations exceeded 4 X MIG. A notable PAE was detected for flucytosine against both Candida and Cryptococcus species that persisted 2 to 4 h. These in vitro data suggest that flucytosine is predominately a concentration-independent fungistatic agent at clinically achieved serum concentrations. This pharmacodynamic characteristic coupled with the persistent PAE and the relatively long half-life of flucytosine in humans (>5 h), suggests lower daily dosing may possible without loss of antifungal efficacy. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:101 / 105
页数:5
相关论文
共 16 条
[1]  
ANDES DA, 1998, INT C ANT AG CHEM
[2]   COMPARISON OF FLUCONAZOLE, AMPHOTERICIN-B AND FLUCYTOSINE IN TREATMENT OF A MURINE MODEL OF DISSEMINATED INFECTION WITH CANDIDA-GLABRATA IN IMMUNOCOMPROMISED MICE [J].
ATKINSON, BA ;
BOUTHET, C ;
BOCANEGRA, R ;
CORREA, A ;
LUTHER, MF ;
GRAYBILL, JR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 35 (05) :631-640
[3]   COMPARISON OF AMPHOTERICIN-B ALONE AND COMBINED WITH FLUCYTOSINE IN THE TREATMENT OF CRYPTOCCAL MENINGITIS [J].
BENNETT, JE ;
DISMUKES, WE ;
DUMA, RJ ;
MEDOFF, G ;
SANDE, MA ;
GALLIS, H ;
LEONARD, J ;
FIELDS, BT ;
BRADSHAW, M ;
HAYWOOD, H ;
MCGEE, ZA ;
CATE, TR ;
COBBS, CG ;
WARNER, JF ;
ALLING, DW .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 301 (03) :126-131
[4]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[5]  
CUTLER RE, 1978, CLIN PHARMACOL THER, V24, P333
[6]   EVOLVING ROLE OF FLUCYTOSINE IN IMMUNOCOMPROMISED PATIENTS - NEW INSIGHTS INTO SAFETY, PHARMACOKINETICS, AND ANTIFUNGAL THERAPY [J].
FRANCIS, P ;
WALSH, TJ .
CLINICAL INFECTIOUS DISEASES, 1992, 15 (06) :1003-1018
[7]   FLUCONAZOLE, D0870, AND FLUCYTOSINE TREATMENT OF DISSEMINATED CANDIDA-TROPICALIS INFECTIONS IN MICE [J].
GRAYBILL, JR ;
NAJVAR, LK ;
HOLMBERG, JD ;
LUTHER, MF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (04) :924-929
[8]   TREATMENT OF FUNGAL INFECTIONS WITH FLUCYTOSINE [J].
HARDER, EJ ;
HERMANS, PE .
ARCHIVES OF INTERNAL MEDICINE, 1975, 135 (02) :231-237
[9]   Efficacy of continuous flucytosine infusion against Candida lusitaniae in experimental hematogenous murine candidiasis [J].
Karyotakis, NC ;
Anaissie, EJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (12) :2907-2908
[10]   Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods [J].
Klepser, ME ;
Ernst, EJ ;
Lewis, RE ;
Ernst, ME ;
Pfaller, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) :1207-1212